Navigation Links
OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
Date:1/4/2011

FT. LAUDERDALE, Fla., Jan. 4, 2011 /PRNewswire/ -- OrbusNeich today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of the company's Genous endothelial progenitor cell (EPC) capture technology.

The patent (U.S. Pat. No. US 7,803,183) covers a coating on an implantable medical device that has one or more layers of a matrix.  Incorporated into the matrix are antibodies or antibody fragments that allow for capture in vivo of circulating EPCs.

"This patent further expands OrbusNeich's unique intellectual property portfolio of the Genous technology," said Robert Cottone, vice president of intellectual property and technologies at OrbusNeich. "We are continuing to develop our pro-healing technology for our next generation stent platform, which combines both luminal cell capture with abluminal drug elution and is currently in clinical trial evaluation."

About Genous  

Genous is OrbusNeich's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which  has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innov
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OrbusNeichs Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
2. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
3. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
4. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
5. OrbusNeichs Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
6. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
7. Data Show OrbusNeichs Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
8. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients
9. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
10. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
11. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)...  In anticipation of the upcoming MEDevice San Diego ... the first time. Industry Overview: Medtech & Life Sciences ... snapshot of San Diego,s critical involvement ... latest employment statistics to current venture capital investment trends, the ... such a vital part of the global medical device ...
(Date:8/28/2014)... 28, 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite leadership ... has published a case study highlighting one ... Course . In September and October 2014, Academy Leadership ... Albuquerque , Indianapolis , Salt Lake ... - http://photos.prnewswire.com/prnh/20140828/140814 Leadership training ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... SEATTLE, Aug. 22 Vical Incorporated (Nasdaq:,VICL) announced ... vaccine Phase 2a,clinical trials, using a plasmid DNA ... and manufactured by Vical, reinforced previously,reported Phase 1 ... was safe and well-tolerated, and was effective in ...
... - Alfacell Corporation,(Nasdaq: ACEL ) today announced ... Oncology (2007; Vol. 31, Issue 3: 663-669) reports ... cell types and tumor cell lines. The observed ... cytotoxic effect on cancer cells and,mechanistic synergism with ...
Cached Medicine Technology:Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 2Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 3Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 2Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 3
(Date:8/29/2014)... HealthDay Reporter THURSDAY, Aug. ... American babies are getting the vaccines they need to ... Thursday. More than 90 percent of children are ... (MMR); polio; hepatitis B and chickenpox (varicella), according to ... "Nationally, vaccination among children 19 to 35 months of ...
(Date:8/29/2014)... Floors of hospitals and other medical facilities tend ... patients are relegated to lying down or sitting due ... Two inventors from Perrysburg, Ohio, have designed the patent-pending ... special pair of socks helps prevent slips and falls ... relegated to beds or chairs from standing and walking ...
(Date:8/29/2014)... -- Selling cigarettes in plain packages doesn,t increase the ... sales in small stores, according to new research from ... industry when it tried to prevent Australia from becoming ... packaging for tobacco products in 2012. Similar legislation is ... Researchers surveyed nearly 2,000 adult smokers in Australia ...
(Date:8/29/2014)... Vancouver, BC (PRWEB) August 29, 2014 ... announced that the company will now be selling purse-sized ... in such a way that they can be carried ... are they portable, the purse-sized range at Honey Gifts ... A long battery life and rechargeable batteries are common ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Evolutions ... Santa Barbara in the Santa Barbara News-Press Readers’ Choice ... won the Readers’ Choice poll as Best Medical Spa. ... 2014 reads the following about Evolutions Medical Spa recognition: ... but it is recognized as a top-notch, cutting-edge medical ...
Breaking Medicine News(10 mins):Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Study Counters Critics of Plainer Cigarette Packaging 2Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 3
... UC Irvine Medical Center recently received a Silver Medal of ... for its role in supporting organ and tissue donation. ... the highest-performing 12-month period between Oct. 1, 2008, and March ... commended in the seven-county Greater Los Angeles area served by ...
... THURSDAY, Dec. 2 (HealthDay News) -- The suicide rate among ... than among civilian women, a new study has found. ... between 2004 and 2007. In the 18-to-34 age group, there ... 33,257,362 nonveterans. That suicide rate amounted to one out ...
... arthritis drug reduces the incidence of non-melanoma skin cancers ... to a study published this week in the ... COX-2 inhibitor celecoxib (brand name Celebrex), which is currently ... acute pain in adults led to a 62 percent ...
... a lawyer, a politician, a professional athlete, an environmentalist or ... some researchers. Still others say the driving force is our ... But a new child-development theory bridges those two models, says ... Holden,s theory holds that the way a child turns out ...
... early in life led to an accumulation of abdominal fat and ... according to new research. Animals exposed to the fine-particulate air ... and higher blood sugar levels than did animals eating the same ... the polluted air for six hours a day, five days a ...
... From microscopy to computer tomography (CT) scans, imaging ... research, but obtaining high-quality images often requires advanced ... a project which launches its preparatory phase today, ... access to state-of-the-art imaging technologies at all levels ...
Cached Medicine News:Health News:UC Irvine Medical Center is recognized for its commitment to organ donation 2Health News:Female Vets Much More Likely to Commit Suicide, Study Finds 2Health News:Widely used arthritis pill protects against skin cancer 2Health News:Widely used arthritis pill protects against skin cancer 3Health News:Beyond nature vs. nurture: Parental guidance boosts child's strengths, shapes development 2Health News:Beyond nature vs. nurture: Parental guidance boosts child's strengths, shapes development 3Health News:Beyond nature vs. nurture: Parental guidance boosts child's strengths, shapes development 4Health News:Polluted air increases obesity risk in young animals 2Health News:Polluted air increases obesity risk in young animals 3Health News:Better imaging from bench to bedside 2
... Physician-office® is an internet ... (Solo practice, group practice ... complete their normal duties ... is a front office ...
... is a modular, Electronic Medical Record (EMR) system ... create a patient chart. ChartMaker is an ... M compliant patient notes, medical reports, letters, and ... ChartMaker is designed to be installed in a ...
... original EMR companies, with a wealth and ... With over a decade of clinical and ... design, corporate level training and support, enables ... medical practice to EMR. The unparalleled HL7 ...
... is dedicated to serving the needs ... ultimate tool to,run a better orthopaedic ... records software.,AcerMed's Orthopaedic-Edition EMR software has ... surgeons across the country resulting in ...
Medicine Products: